The FDA says it needs another four weeks to finish reviewing Mannkind's (MNKD +5.4%) new drug...

|By:, SA News Editor

The FDA says it needs another four weeks to finish reviewing Mannkind's (MNKD +5.4%) new drug application for Afrezza, an inhaled-insulin product. Mannkind, which has no products on the market, had been expecting FDA approval tomorrow. (PR)